Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
References
Additional references
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington (DC): American Psychiatric Association, 1980.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington (DC): American Psychiatric Association, 1987.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington (DC): American Psychiatric Association, 1994.
American Psychiatric Association. Diagnostic and StatisticalManual of Mental Disorders (DSM‐5). Washington (DC): American Psychiatric Association, 2013.
Bradley C. The behavior of children receiving benzedrine. The American Journal of Psychiatry 1937;94(3):577‐85. [DOI: 10.1176/ajp.94.3.577]
Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007‐2010. JAMA 2012;307(17):1838‐47. [DOI: 10.1001/jama.2012.3424; PUBMED: 22550198]
Castells X, Ramos‐Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, et al. Efficacy of methylphenidate for adults with attention‐deficit hyperactivity disorder: a meta‐regression analysis. CNS Drugs 2011;25(2):157‐69. [DOI: 10.2165/11539440‐000000000‐00000; PUBMED: 21254791]
Caye A, Rocha TB, Anselmi L, Murray J, Menezes AM, Barros FC, et al. Attention‐deficit hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late‐onset syndrome. JAMA Psychiatry 2016;73(7):705‐12. [DOI: 10.1001/jamapsychiatry.2016.0383; PUBMED: 27192050]
Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W. Methylphenidate hydrochloride given with or before breakfast: effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983;72(1):56‐9. [PUBMED: 6866592]
Charach A, Yeung E, Climans T, Lillie E. Childhood attention‐deficit hyperactivity disorder and future substance use disorders: comparative meta‐analyses. Journal of the American Academy of Child and Adolescent Psychiatry 2011;50(1):9‐21. [DOI: 10.1016/j.jaac.2010.09.019; PUBMED: 21156266]
Charach A, Carson P, Fox S, Ali MU, Beckett J, Lim CG. Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics 2013;131(5):e1584–604. [DOI: 10.1542/peds.2012‐0974; PUBMED: 23545375]
Chen Q, Sjölander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention‐deficit hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014;348:g3769. [DOI: 10.1136/bmj.g3769; PMC4062356; PUBMED: 24942388]
Cheng YS, Shyu YC, Lee SY, Yuan SS, Yang CJ, Yang KC, et al. Trends, characteristics, and pharmacotherapy of adults diagnosed with attention‐deficit hyperactivity disorder: a nationwide survey in Taiwan. Neuropsychiatric Disease and Treatment 2017;13:643‐51. [DOI: 10.2147/NDT.S126438; PMC5338966; PUBMED: 28280346]
Chou R, Aronson N, Atkins D, Ismaila AS, Santaguida P, Smith DH, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health‐care program. Journal of Clinical Epidemiology 2010;63(5):502‐12. [DOI: 10.1016/j.jclinepi.2008.06.007; PUBMED: 18823754]
Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Healthcare. York (UK): Centre for Reviews & Dissemination, 2009.
Curtin F, Altman DG, Elbourne D. Meta‐analysis combining parallel and cross‐over clinical trials I: Continuous outcomes. Statistics in Medicine 2002;21(15):2131‐44. [DOI: 10.1002/sim.1207; PUBMED: 12210631]
Deeks JJ, Higgins JPT, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.
Dresel S, Krause J, Krause KH, LaFougere C, Brinkbäumer K, Kung HF, et al. Attention deficit hyperactivity disorder: binding of [99mTc]‐TRODAT‐1 to the dopamine transporter before and after methylphenidate treatment. European Journal of Nuclear Medicine 2000;27(10):1518‐24. [PUBMED: 11083541]
DynaMed Plus. Attention deficit hyperactivity disorder (ADHD) in adults: record number 231898. www.dynamed.com/topics/dmp˜AN˜T231898/Attention‐deficit‐hyperactivity‐disorder‐ADHD‐in‐adults (accessed August 30 2016).
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. [PMC2127453; PUBMED: 9310563]
Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. [PUBMED: 11914310]
European Medicines Agency. Elements recommended for inclusion in summaries of product characteristics for methylphenidate‐containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_31/WC500011184.pdf (accessed 22 January 2018).
Thomson Reuters. EndNote X8. Version Version 8.2. Philadelphia (PA): Thomson Reuters, 2017.
Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Current Neuropharmacology 2008;6(4):322–8. [DOI: 10.2174/157015908787386069; PMC2701285; PUBMED: 19587853]
Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar‐Gaxiola S, Al‐Hamzawi A, et al. The descriptive epidemiology of DSM‐IV adult ADHD in the World Health Organization World Mental Health Surveys. Attention Deficit and Hyperactivity Disorders 2017;9(1):47‐65. [DOI: 10.1007/s12402‐016‐0208‐3; PMC5325787; PUBMED: 27866355]
Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):769‐73. [PUBMED: 1619456]
Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities?. Annals of Family Medicine 2006;4(2):104‐8. [DOI: 10.1370/afm.516; PMC1467012; PUBMED: 16569712]
Fredriksen M, Halmøy A, Faraone S, Haavik J. Long‐term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. European Neuropsychopharmacology 2013;23:508‐27.
Golder S, McIntosh HM, Duffy S, Glanville J, Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Information and Libraries Journal 2006;23(1):3‐12. [10.1111/j.1471‐1842.2006.00634.x; PUBMED: 16466494]
Golder S, Loke YK, Bland M. Meta‐analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Medicine 2011;8(5):e1001026. [DOI: doi.org/10.1371/journal.pmed.1001026; PMC3086872; PUBMED: 21559325]
Golder S, Loke YK. The contribution of different information sources for adverse effects data. International Journal of Technology Assessment in Health Care 2012;28(2):133‐7. [DOI: 10.1017/S0266462312000128; PUBMED: 22559754 ]
Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366]
Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta‐analysis. BMC Psychiatry 2011;11:176. [DOI: 10.1186/1471‐244X‐11‐176; PMC3229459; PUBMED: 22074258]
Heal DJ, Pierce DM. Methylphenidate and its isomers:their role in the treatment of attention‐deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006;20(9):713‐38. [PUBMED: 16953648]
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Sterne JAC, Savović J, Page MJ, Hrbjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editor(s). Cochrane Methods. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). Available from sites.google.com/site/riskofbiastool/welcome/rob‐2‐0‐tool. [DOI: 10.1002/14651858.CD201601]
Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.
International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 19 April 2017).
Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine 2009;169(19):1737‐9. [DOI: 10.1001/archinternmed.2009.313; PUBMED: 19858427]
Jørgensen L, Paludan‐Mlüler AS, Laursen DRT, Savović J, Boutron I, Sterne JAC, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non‐Cochrane reviews. Systematic Reviews 2016;5:80. [DOI: 10.1186/s13643‐016‐0259‐8; PMC4862216]
Kambeitz J, Romanos M, Ettinger U. Meta‐analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. The Pharmacogenomics Journal 2014;14(1):77–84. [DOI: 10.1038/tpj.2013.9; PUBMED: 23588108]
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. The American Journal of Psychiatry 2006;163(4):716–23. [DOI: 10.1176/ajp.2006.163.4.716; PMC2859678; PUBMED: 16585449]
Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment 2008;4(2):389–403. [PMC2518387]
Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever‐Stille KA, Arndt S, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry 2001;13(3):129‐34. [PUBMED: 11791949]
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Götzsche PC, Ioannidis JA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. [DOI: 10.1136/bmj.b2700; PMC2714672; PUBMED: 19622552]
Loke YK, Proce D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Loke YK, Mattishent K. If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of security. Canadian Medical Association Journal 2015;187(1):15‐6. [DOI: 10.1503/cmaj.141344; PMC4284159; PUBMED: 25404394]
Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Polanczyk CA, et al. Long‐term efficacy of methylphenidate immediate‐release for the treatment of childhood ADHD: a systematic review and meta‐analysis. Journal of Attention Disorders 2017;21(1):3‐13. [DOI: 10.1177/1087054714559643; PUBMED: 25501355]
Maidment ID. Efficacy of stimulants in adult ADHD. The Annals of Pharmacotherapy 2003;37(12):1884‐90. [DOI: 10.1345/aph.1D028; PUBMED: 14632541]
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. Journal of Clinical Epidemiology 2016;75:40‐6. [DOI: 10.1016/j.jclinepi.2016.01.021; PUBMED: 27005575]
Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta‐analysis. The International Journal of Neuropsychopharmacology 2009;12(8):1137–47. [DOI: 10.1017/S1461145709990198; PUBMED: 19580697]
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. BMJ 2009;339:b2535. [DOI: 10.1136/bmj.b2535]
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta‐analysis protocols (PRISMA‐P) 2015 statement. Systematic Reviews 2015;4:1. [DOI: 10.1186/2046‐4053‐4‐1; PMC4320440; PUBMED: 25554246]
National Heart, Lung, and Blood Institute. Quality assessment tool for observational cohort and cross‐sectional studies. www.nhlbi.nih.gov/health‐topics/study‐quality‐assessment‐tools(accessed March 2014).
National Institute for Clinical Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management. Clinical Guideline: 72. London (UK): The British Psychological Society and the Royal College of Psychiatrists, 2016.
National Institute of Mental Health. Attention deficit hyperactivity disorder. www.nimh.nih.gov/health/topics/attention‐deficit‐hyperactivity‐disorder‐adhd/index.shtml(accessed March 2016).
Novartis Pharmaceuticals Corporation. RITALIN® Hydrochloride (Methylphenidate Hydrochloride USP Tablets), Ritalin‐SR® (Methylphenidate Hydrochloride USP Sustained‐Release Tablets), Rx Only: Prescribing Information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2007.
O’Connor D, Green S, Higgins JPT. editor(s). Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Perini E, Junqueira DRG, Lana LGC, Luz TCB. Prescription, dispensation and marketing patterns of methylphenidate. Revista de Saúde Pública 2014;48(6):873‐80. [DOI: 10.1590/S0034‐8910.2014048005234; PMC4285829; PUBMED: 26039389]
Perrie Y, Rades T. Pharmaceutics ‐ Drug Delivery and Targeting. 2nd Edition. London (UK): Pharmaceutical Press, 2012.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. The American Journal of Psychiatry 2007;164(6):942–8. [DOI: 10.1176/ajp.2007.164.6.942; PUBMED: 17541055]
Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta‐regression analysis. International Journal of Epidemiology 2014;43(2):434‐42. [DOI: 10.1093/ije/dyt261; PMC4817588; PUBMED: 24464188]
Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S. Long‐acting versus short‐acting methylphenidate for paediatric ADHD: a systematic review and meta‐analysis of comparative efficacy. BMJ Open 2013;3(3):e002312. [DOI: 10.1136/bmjopen‐2012‐002312; PMC3612754; PUBMED: 23503579]
Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non‐randomized studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org.
Reichow B, Volkmar FR, Bloch MH. Systematic review and meta‐analysis of pharmacological treatment of the symptoms of attention‐deficit/hyperactivity disorder in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders 2013;43(10):2435–41. [DOI: 10.1007/s10803‐013‐1793‐z; PMC3787525; PUBMED: 23468071]
Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 2014;349:g6501. [DOI: 10.1136/bmj.g6501]
Schabram I, Henkel K, Mohammadkhani SS, Dietrich C, Schmaljohann J, Winz O, et al. Acute and sustained effects of methylphenidate on cognition and presynaptic dopamine metabolism: an [18F]FDOPA PET study. The Journal of Neuroscience 2014;34(44):14769‐76. [DOI: 10.1523/JNEUROSCI.1560‐14.2014; PUBMED: 25355228]
Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of Orlistat: a document analysis. PLoS Medicine 2016;13(8):e1002101. [DOI: 10.1371/journal.pmed.1002101; PMC4987052; PUBMED: 27529343]
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sibley MH, Mitchell JT, Becker SP. Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. Lancet Psychiatry 2016;3(12):1157–65. [DOI: 10.1016/S2215‐0366(16)30190‐0; PUBMED: 27745869]
Somkuwar SS, Kantak KM, Dwoskin LP. Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder. Journal of Neuroscience Methods 2015;252:55‐63. [DOI: 10.1016/j.jneumeth.2015.02.002; PMC4522381; PUBMED: 25680322]
Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double‐blind, crossover comparison of methylphenidate and placebo in adults with childhood‐onset attention‐deficit hyperactivity disorder. Archives of General Psychiatry 1995;52(6):434‐43. [PUBMED: 7771913]
Stein MA, Blondis TA, Schnitzler ER, O'Brien T, Fishkin J, Blackwell B, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996;98((4 Pt 1)):748‐56. [PUBMED: 8885956]
Sterne JAC, Egger M, Moher D, Boutron I, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston M, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomized studies of interventions. BMJ 2016;355:i4919. [DOI: doi.org/10.1136/bmj.i491; PMC5062054; PUBMED: 27733354]
Storebo OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews 2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2]
Sweetman SC, editor(s). Martindale: The Complete Drug Reference. 38. London (UK): Pharmaceutical Press, 2014. [ISBN 9780857111395 0857111396]
Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention‐deficit hyperactivity disorder: a systematic review and meta‐analysis. Pediatrics 2015;135(4):e994‐1001. [DOI: 10.1542/peds.2014‐3482; PUBMED: 25733754]
US FDA. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. www.fda.gov (accessed 22 January 2018).
Ustun B, Adler LA, Rudin C, Faraone SV, Spencer TJ, Berglund P, et al. The World Health Organization Adult Aattention‐Deficit Hyperactivity Disorder Self‐report Screening Scale for DSM‐5. JAMA Psychiatry 2017;74(5):520‐6. [DOI: 10.1001/jamapsychiatry.2017.0298; PMC5470397; PUBMED: 28384801]
Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters LM, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality, 2008:193‐221. [PUBMED: 22479713]
Viswanathan M, Ansari MT, Berman ND, Chang S, Hartling L, McPheeters M, et al. Table A‐3. McMaster tool for assessing quality of harms assessment and reporting in study reports (McHarm). Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality, 2008:A‐6.
Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. The Journal of neuroscience 2001;21(2):RC121. [PUBMED: 11160455]
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. Journal of Attention Disorders 2002;6(Suppl 1):S31‐43. [PUBMED: 12685517]
Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, et al. Pharmacokineticsof methylphenidate in man, rat and monkey. The Journal of Pharmacology and Experimental Therapeutics 1983;226(2):382−86. [PUBMED: 6410043]
World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva (CH): World Health Organization, 1992.
WHO Collaborating Centre for Drug Statistic Methodology. ATC/DDD Index 2017. www.whocc.no/atcddd (accessed 20 Apr 2017).
Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J, et al. Randomized, double‐blind, placebo‐controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention‐deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioral and Brain Functions 2010;6(1):34. [DOI: 10.1186/1744‐9081‐6‐34; PMC2908054; PUBMED: 20576091]
Wilens TE. Drug therapy for adults with attention‐deficit hyperactivity disorder. Drugs 2003;63(22):2395‐411. [DOI: 10.2165/00003495‐200363220‐00002; PUBMED: 14609347]
Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ 2014;348:f7668. [DOI: 10.1136/bmj.f7668]
Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ 2016;352:i157. [DOI: 10.1136/bmj.i157; PUBMED: 26830668]
